Investigational drug · Phase 3
INBRX-106
Also called: Ordastobart
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Head and Neck Squamous Cell Carcinoma (HNSCC), HPV Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC).
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "INBRX-106"
First trial start
2024
May 14, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "INBRX-106", any sponsor or status.
Conditions studied
As listed on its trial records.
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- HPV Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC)
Approved drugs for the same conditions: Head and neck cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "INBRX-106" as an intervention, largest first.
- Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)Pivotal-lookingRecruiting
Inhibrx Biosciences, IncIndustry
NCT06295731 · 450 participants (planned) · Start May 14, 2024 · Primary completion Dec 2029
Drug: INBRX-106; Pembrolizumab · For: Head and Neck Squamous Cell Carcinoma (HNSCC); HPV Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC)
Sites: Duarte, California; Los Angeles, California; Sacramento, California · 89 sites in all
- Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)Pivotal-lookingRecruiting
Inhibrx Biosciences, IncIndustry
NCT04198766 · 340 participants (planned) · Start Dec 10, 2019 · Primary completion Jul 2033
Drug: INBRX-106 - Hexavalent OX40 agonist antibody; pembrolizumab 200 mg and 8 more · For: Solid Tumor; Non-Small Cell Lung Cancer; Head and Neck Cancer and 5 more
Sites: Duarte, California; Glendale, California; La Jolla, California · 60 sites in all
- A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid TumorsCompleted
Elpiscience Biopharma, Ltd.Industry
NCT04991506 · 30 participants · Start Oct 15, 2021 · Primary completion May 17, 2024
Drug: ES102; JS001 · For: Solid Tumor; Neoplasms; Malignant Tumor
Sites: Changchun, China
- A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung CancerActive, not recruiting
Elpiscience (Suzhou) Biopharma, Ltd.Industry
NCT06623136 · 30 participants · Start Apr 30, 2025 · Primary completion Feb 28, 2027
Drug: ES102; Toripalimab · For: Non-Small Cell Lung Cancer
Sites: Beijing, China; Zhengzhou, China; Nanchang, China · 9 sites in all
Elpiscience Biopharma, Ltd.Industry
NCT04730843 · 18 participants · Start Apr 1, 2021 · Primary completion Mar 1, 2024
Drug: ES102 · For: Solid Tumors; Neoplasms; Malignant Tumor
Sites: Changchun, China
Providence Health & ServicesAcademic, hospital or other
NCT06353997 · 12 participants (planned) · Start Sep 5, 2024 · Primary completion Jun 2027
Drug: Pembrolizumab; INBRX-106 · For: Triple Negative Breast Cancer
Sites: Los Angeles, California; Portland, Oregon · 3 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- OX40/OX40L modulation: A target for regulating T cells in cutaneous inflammatory disorders.
Gupta AK, Steriopoulos J, Economopoulos V, et al. · J Eur Acad Dermatol Venereol 2026
- INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering.
Holay N, Yadav R, Ahn SJ, et al. · J Immunother Cancer 2025
Also in development for Head and Neck Squamous Cell Carcinoma (HNSCC)
- AK129Phase 22 trials
Akeso · Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Adenocarcinoma
- AP203Phase 21 trial
AP Biosciences Inc. · Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC)
- FDC fianlimabPhase 21 trial
Regeneron · Head and Neck Squamous Cell Carcinoma (HNSCC)
- GEN1042Phase 21 trial
Genmab · Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
- GTAEXS617REC-617Phase 21 trial
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. · Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC)
- MT-4561Phase 21 trial
Tanabe Pharma America, Inc. · Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.